TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28646841

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (oral anti‐spastic medications and stretching exercises)
Number of subjects: 28
Study: 24249542

Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle therapy (PFMT) with biofeedback once a week for 4 weeks preoperatively
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 122
Study: 23897970

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg orally twice per day for 14 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 21724008

Group type: EXPERIMENTAL
Intervention: Mannitol (20%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hypertonic isoncotic saline (HIS)
Number of subjects: 29
Study: 19682403

Group type: EXPERIMENTAL
Intervention: B-vitamins supplementation for 3 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemic subjects
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 17912233

Group type: EXPERIMENTAL
Intervention: Uretero-vescical anastomosis according to Lich-Gregoir (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Uretero-vescical anastomosis according to Knechtle (group B)
Number of subjects: 36
Study: 15090796

Group type: EXPERIMENTAL
Intervention: CD4 cell count‐driven structured treatment interruption (STI) strategy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Continuous highly active antiretroviral therapy
Number of subjects: 69
Study: 11253966

Group type: EXPERIMENTAL
Intervention: Regimen A (20 mg/m2 cisplatin on days 1-5, 100 mg/m2 etoposide on days 1-5, 30 kU bleomycin on days 1, 8, and 15, repeated every 21 days)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Regimen B (100 mg/m2 cisplatin on day 1, 120 mg/m2 etoposide on days 1-3, 30 kU bleomycin on day 1, repeated every 21 days)
Number of subjects: 166
Study: 9633761

Group type: EXPERIMENTAL
Intervention: Prednisone plus paracetamol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Paracetamol only
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 7706572

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 32 vpm
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 64 vpm
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 128 vpm
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 512 vpm
Number of subjects: 5
Study: 3664948

Group type: EXPERIMENTAL
Intervention: Group B: early instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Group A: early instillation of adriamycin (30 mg/30 ml)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Group C: delayed instillation of adriamycin (30 mg/30 ml)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Group D: delayed instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Early instillation groups
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Delayed instillation groups
Number of subjects: 199
Study: 29898707

Group type: EXPERIMENTAL
Intervention: Intravenous TXA 10 mg/kg IV 10 min prior to tourniquet deflation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical TXA 1.0 g diluted in 50 ml normal saline injected into surgical site prior to tourniquet deflation
Number of subjects: 64
Study: 28065180

Group type: EXPERIMENTAL
Intervention: Personalised dietary advice
Number of subjects: 0
Study: 24999481

Group type: EXPERIMENTAL
Intervention: NHS in one step (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NHS with retest (Group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall incidence of hearing loss
Number of subjects: 0
Study: 24360041

Group type: EXPERIMENTAL
Intervention: TACE plus CT-guided percutaneous RFA in special location group
Number of subjects: 36

Group type: COMPARATOR
Intervention: TACE plus CT-guided percutaneous RFA in non-special location group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complications in special location group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Complications in non-special location group
Number of subjects: 36
Study: 20572834

Group type: EXPERIMENTAL
Intervention: Mandibular implant treatment with two implants and a new denture with magnet-, ball-socket, and bar-clip attachments
Number of subjects: 18
Study: 18438563

Group type: EXPERIMENTAL
Intervention: Carbonated drink
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 3
Study: 17030762

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12746776

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment for HCV infection
Number of subjects: 30
Study: 11319683

Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (12 million IU by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (7.5 MIU twice a day, sc, every 8 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (3 MIU twice a day, sc, every 4 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 61
Study: 9129766

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) during CVVHDF
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CVVHDF
Number of subjects: 6
Study: 8184997

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (12 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Supportive drug maintenance and slow, flexible drug taper (alprazolam-only group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined treatment (cognitive behavioral treatment + supportive drug maintenance)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Alprazolam-only group
Number of subjects: 21
Study: 3332681

Group type: EXPERIMENTAL
Intervention: Ganglioside administration (40 mg intramuscular daily)
Number of subjects: 30
Study: 31153990

Group type: EXPERIMENTAL
Intervention: Etizolam 0.25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Etizolam 1.00 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28501140

Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 207
Study: 25883952

Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (10 sessions)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (10 sessions)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Medical therapy and isometric lumbar exercises (10 days)
Number of subjects: 65
Study: 24520889

Group type: EXPERIMENTAL
Intervention: Primary bereavement care intervention by trained family physicians for widows (43 widows, 7 sessions from 4th to 13th month after loss)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ordinary appointments by untrained family physicians for widows (44 widows, 7 sessions with the same schedule)
Number of subjects: 87
Study: 21624837

Group type: COMPARATOR
Intervention: Hepatic artery embolization (HAE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Portal vein (PV) embolization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of PV embolization to HAE
Number of subjects: 50
Study: 18049092

Group type: EXPERIMENTAL
Intervention: N-butylscopolamine (20 mg intravenously)
Number of subjects: 72
Study: 16605293

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 12960187

Group type: COMPARATOR
Intervention: (18)F-FDG
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: (18)F-FLT
Number of subjects: 26
Study: 10834774

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.1% ropivacaine with fentanyl 2 microg/mL and epinephrine 1:400,000 (REF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Epidural saline
Number of subjects: 34
Study: 9663837

Group type: EXPERIMENTAL
Intervention: Alosetron (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8459057

Group type: EXPERIMENTAL
Intervention: 1,000-calorie meal
Number of subjects: 20
Study: 31190058

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28395396

Group type: EXPERIMENTAL
Intervention: Lavender-sandalwood aromatherapy tab
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Orange-peppermint aromatherapy tab
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 24859616

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 0
Study: 23408562

Group type: EXPERIMENTAL
Intervention: Internet + PCD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Internet- alone
Number of subjects: 50
Study: 22696626

Group type: EXPERIMENTAL
Intervention: Whole body vibration (frequency=28 Hz; amplitude 0.97 mm)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control condition (machine turned off)
Number of subjects: 4
Study: 18398548

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15816569

Group type: EXPERIMENTAL
Intervention: High bolus dose of cisatracurium (0.4 mg kg(‐1)) in Group 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium (0.1 mg kg(‐1) at induction followed by continuous infusion) in Group 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total amount of cisatracurium used
Number of subjects: 20
Study: 12598068

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 30
Study: 10547208

Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin and sulphonylureas (glibenclamide 10.5 mg daily)
Number of subjects: 15
Study: 8638193

Group type: EXPERIMENTAL
Intervention: Mesalamine derivatives of sulfasalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer steroid preparations (investigational)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (6-mercaptopurine, azathioprine, methotrexate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids and sulfasalazine (traditional therapy)
Number of subjects: 0
Study: 1808488

Group type: EXPERIMENTAL
Intervention: Kybernin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no Kybernin)
Number of subjects: 32
Study: 6619270

Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment (3-5 weeks)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment
Number of subjects: 7
Study: 31021875

Group type: EXPERIMENTAL
Intervention: Intraoperative vertebral anesthesia (group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional local anesthesia (group A)
Number of subjects: 64
Study: 29167041

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral stress management program (IB-CBSM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (CG) based on distraction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both IB-CBSM and CG
Number of subjects: 93
Study: 27560995

Group type: EXPERIMENTAL
Intervention: Daily motivation and self-efficacy assessments via ecological momentary assessment (EMA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control for between-person associations and prior drinking
Number of subjects: 96
Study: 24293175

Group type: EXPERIMENTAL
Intervention: Fluoroscopic measurement of right-to-left interlead distance (2DAP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Fluoroscopic measurement of right-to-left interlead distance (2DLL)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Response to CRT
Number of subjects: 49
Study: 22389967

Group type: EXPERIMENTAL
Intervention: Nociceptive trigeminal inhibitory tension suppression system (NTI-tss)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splint (OS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Micro-arousal index
Number of subjects: 10
Study: 19786664

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: BCL6 breakpoint
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Immunohistochemical markers (CD10, BCL6, MUM1/IRF4, LMO2, FOXP1)
Number of subjects: 119
Study: 17715638

Group type: EXPERIMENTAL
Intervention: Spironolactone 100‐200 mg/d and furosemide 20‐40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial therapeutic paracentesis, transjugular intrahepatic stent‐shunt (TIPS), peritoneovenous shunt, liver transplantation
Number of subjects: 0
Study: 15118188

Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplementation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 11780794

Group type: EXPERIMENTAL
Intervention: Dual-task condition (tapping task)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard conditions (control group)
Number of subjects: 39
Study: 9715735

Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouth breathing
Number of subjects: 10
Study: 8152445

Group type: EXPERIMENTAL
Intervention: Propranolol (mean dose 212 +/- 68 mg per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 70
Study: 3291041

Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30885799

Group type: EXPERIMENTAL
Intervention: Extended Duration Work Roster (EDWR) with shifts ≥24 h
Number of subjects: 6577

Group type: COMPARATOR
Intervention: Rapidly Cycling Work Roster (RCWR) with shifts limited to a maximum of 16 h
Number of subjects: 6577
Study: 28944752

Group type: COMPARATOR
Intervention: DVD intervention (self-guided breathing retraining with DVD and booklet)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Face-to-face physiotherapy intervention (three sessions with a respiratory physiotherapist)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Control group (usual care)
Number of subjects: 655

Group type: COMPARATOR
Intervention: DVD intervention
Number of subjects: 655

Group type: COMPARATOR
Intervention: Face-to-face physiotherapy intervention
Number of subjects: 655
Study: 26158895

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via hypoglossal nerve
Number of subjects: 0
Study: 24112951

Group type: EXPERIMENTAL
Intervention: rVIIa-FP (140, 300, 500, 750, or 1000 μg kg(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rVIIa-FP (1000 μg kg(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Number of subjects: 40
Study: 21741829

Group type: COMPARATOR
Intervention: Capecitabine (X) 2500mg/m² on days 1-14, q3w
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus capecitabine (XH) 6 (8)mg/kg, q3w
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Continuation/restart of anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression
Number of subjects: 151

Group type: COMPARATOR
Intervention: No anti-HER2 treatment after 2nd progression
Number of subjects: 151
Study: 19629145

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Portland Cement (PC)
Number of subjects: 30
Study: 16500339

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) with 90 mL of oral sodium phosphate (NaP)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 162
Study: 12831259

Group type: EXPERIMENTAL
Intervention: Simulators of malingering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (not feigning)
Number of subjects: 0
Study: 12580206

Group type: EXPERIMENTAL
Intervention: Object display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Object Minus Shapes display
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSSI Numeric display
Number of subjects: 0
Study: 8880181

Group type: EXPERIMENTAL
Intervention: Attended EOAEs generated by 1 or 2 kHz tone pips
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unattended EOAEs generated by 1 or 2 kHz tone pips
Number of subjects: 70
Study: 1519210

Group type: EXPERIMENTAL
Intervention: Ivy method
Number of subjects: 134

Group type: COMPARATOR
Intervention: Simplate II method (horizontal direction)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Simplate II method (vertical direction)
Number of subjects: 134
Study: 6087702

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Self-regulated oral diet (control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 31
Study: 30995693

Group type: COMPARATOR
Intervention: Face-to-face counselling (usual care)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Noninteractive instructional video
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Interactive video
Number of subjects: 141
Study: 31113448

Group type: EXPERIMENTAL
Intervention: 'high in' warning FOP label
Number of subjects: 3584

Group type: COMPARATOR
Intervention: All tax conditions
Number of subjects: 3584

Group type: COMPARATOR
Intervention: 'sugary drink' taxes
Number of subjects: 3584
Study: 28581356

Group type: EXPERIMENTAL
Intervention: Pertuzumab added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Number of subjects: 4805

Group type: EXPERIMENTAL
Intervention: Pertuzumab in node-positive cohort
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo in node-positive cohort
Number of subjects: 4805

Group type: EXPERIMENTAL
Intervention: Pertuzumab in node-negative cohort
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo in node-negative cohort
Number of subjects: 4805

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4805
Study: 26406018

Group type: EXPERIMENTAL
Intervention: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of a 2.5% NaOCl solution (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of an active silver ion antibacterial solution (Group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Syringe irrigation of a 2.5% NaOCl solution (Group C)
Number of subjects: 300
Study: 23714651

Group type: EXPERIMENTAL
Intervention: Fit-4-Fun program (8-week multi-component intervention)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Fit-4-Fun program
Number of subjects: 213
Study: 20694469

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) treatment, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine, administered once in September, October, and November (3 doses total)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19477300

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 441

Group type: COMPARATOR
Intervention: Low calorie healthy eating approach
Number of subjects: 441
Study: 18046092

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (statin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering with statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15612152

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fluorouracil plus leucovorin (FL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan plus fluorouracil (IFL)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bevacizumab plus IFL
Number of subjects: 2
Study: 11575684

Group type: EXPERIMENTAL
Intervention: All Stars program administered by teachers
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: All Stars program administered by specialists
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1655
Study: 9515799

Group type: EXPERIMENTAL
Intervention: 5FU plus levamisole
Number of subjects: 229

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Ki-ras mutation
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Aneuploidy
Number of subjects: 229
Study: 7997085

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2A treatment
Number of subjects: 35
Study: 3421197

Group type: EXPERIMENTAL
Intervention: L‐[3,3,3‐2H3]alanine
Number of subjects: 20

Group type: COMPARATOR
Intervention: L‐[15N]‐alanine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet in obese subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state in healthy adults
Number of subjects: 20
Study: 29450792

Group type: EXPERIMENTAL
Intervention: Operant procedure with pictorial stimuli in a two-alternative discrimination task
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison to pigeons
Number of subjects: 2
Study: 28452822

Group type: EXPERIMENTAL
Intervention: Valveless Trocar (VT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard Trocar (ST)
Number of subjects: 56
Study: 26134266

Group type: EXPERIMENTAL
Intervention: Facilitated physician discussion groups (19 biweekly sessions for 9 months) with mindfulness and reflection elements
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nontrial cohort (not specified)
Number of subjects: 74